<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>EuroPCR</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Edwards' data shows benefits of early intervention in aortic stenosis</title>
      <description>
        <![CDATA[Edwards Lifesciences Corp. released new economic and clinical data on severe aortic stenosis (AS) demonstrating  intervening in a patient with the disease before symptoms develop can reduce costs to the health care system by $36,000. Data also shows earlier intervention can also lead to fewer follow-ups and hospitalizations for heart failure, after treatment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720278</guid>
      <pubDate>Fri, 23 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720278-edwards-data-shows-benefits-of-early-intervention-in-aortic-stenosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/2-7-TAVR-edwards-sapien3.webp?t=1724185362" type="image/png" medium="image" fileSize="534933">
        <media:title type="plain">Device in heart</media:title>
        <media:description type="plain">The Edwards Sapien 3 TAVR. Credit: Edwards Lifesciences Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Tricares Topaz valve significantly reduces tricuspid regurgitation</title>
      <description>
        <![CDATA[Data from the first-in-human study of Tricares SAS Topaz transcatheter tricuspid valve replacement (TTVR) system, showed it significantly reduced tricuspid regurgitation (TR) in patients treated with the device. The early clinical data at 30 days demonstrated that all patients implanted with Topaz were at a TR grade ‘none’ (0+) or ‘mild’ (1+) following the procedure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720267</guid>
      <pubDate>Thu, 22 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720267-tricares-topaz-valve-significantly-reduces-tricuspid-regurgitation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/TRiCares-Topaz22may25-.webp?t=1747943230" type="image/jpeg" medium="image" fileSize="257979">
        <media:title type="plain">TRiCaresTopaz</media:title>
        <media:description type="plain">Tricares Topaz transcatheter tricuspid valve replacement system. Credit: Tricares</media:description>
      </media:content>
    </item>
    <item>
      <title>Dynamx bioadaptor superior to Resolute Onyx DES</title>
      <description>
        <![CDATA[Three-year data from Elixir Medical Corp.’s Bioadaptor randomized controlled trial showed that patients with coronary artery disease treated with its Dynamx coronary drug-eluting bioadaptor system continued to see lower adverse events rates compared to those treated with Medtronic plc’s Resolute Onyx drug-eluting stent .]]>
      </description>
      <guid>http://www.bioworld.com/articles/720257</guid>
      <pubDate>Wed, 21 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720257-dynamx-bioadaptor-superior-to-resolute-onyx-des</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Elixir-Medical-DynamX-21may25.webp?t=1747864913" type="image/jpeg" medium="image" fileSize="273431">
        <media:title type="plain">Elixir Medical DynamX</media:title>
        <media:description type="plain">Elixir Medical DynamX. Credit: Elixir Medical</media:description>
      </media:content>
    </item>
    <item>
      <title>EMPOWER CAD study confirms benefits of IVL-first strategy in women</title>
      <description>
        <![CDATA[Shockwave Medical Inc., a unit of Johnson & Johnson Medtech, reported positive 30-day results from the EMPOWER CAD trial, which used its intravascular lithotripsy system in women with complex, calcified coronary artery disease. The results from the first prospective, real-world percutaneous coronary intervention study in female patients confirmed the benefit of coronary patients as seen in other retrospective analyses.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720249</guid>
      <pubDate>Tue, 20 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720249-empower-cad-study-confirms-benefits-of-ivl-first-strategy-in-women</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Shockwave-IVL.webp?t=1730496319" type="image/png" medium="image" fileSize="700658">
        <media:title type="plain">Shockwave IVL</media:title>
      </media:content>
    </item>
    <item>
      <title>Boston Scientific hoping to change EU guidelines for use of IVUS during PCI</title>
      <description>
        <![CDATA[Boston Scientific Corp. is hoping to help change European guidelines on the use of intravascular imaging during percutaneous coronary intervention procedures, Emile Mehanna, medical affairs and medical education director, interventional cardiology, EMEA, told BioWorld. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/708580</guid>
      <pubDate>Thu, 23 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708580-boston-scientific-hoping-to-change-eu-guidelines-for-use-of-ivus-during-pci</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Avvigo-plus-23may24.webp?t=1716499339" type="image/jpeg" medium="image" fileSize="161543">
        <media:title type="plain">Avvigo+</media:title>
        <media:description type="plain">Avvigo+ multi-modality guidance system. Credit: Boston Scientific</media:description>
      </media:content>
    </item>
    <item>
      <title>Data shows Elixir’s coronary implant with TRx coating is safe</title>
      <description>
        <![CDATA[Elixir Medical Corp. reported positive 12-month clinical data from the Desyne BDS Plus randomized controlled trial which evaluated its Desyne BDS plus system, a triple drug-eluting coronary implant with site-specific antithrombotic therapeutic coating, against a contemporary, durable polymer drug-eluting stent in the treatment of de novo native coronary artery lesions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708562</guid>
      <pubDate>Tue, 21 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708562-data-shows-elixirs-coronary-implant-with-trx-coating-is-safe</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Thrombosis-blood-clot.webp?t=1676651893" type="image/png" medium="image" fileSize="1702000">
        <media:title type="plain">Illustration of clot forming in blood vessel</media:title>
      </media:content>
    </item>
    <item>
      <title>Notion-2 trial shows similar outcomes for TAVI and SAVR in low-risk patients</title>
      <description>
        <![CDATA[  One-year data from the Notion-2 trial, which compared transcatheter aortic valve implantation (TAVI) with surgical aortic valve replacement (SAVR) in younger low-risk patients with severe tricuspid or bicuspid aortic valve stenosis, showed little difference in clinical outcomes between the two procedures. The results were presented at the recent EuroPCR conference in Paris.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708550</guid>
      <pubDate>Mon, 20 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708550-notion-2-trial-shows-similar-outcomes-for-tavi-and-savr-in-low-risk-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/AAA-abdominal-aortic-aneurysm.webp?t=1699024650" type="image/jpeg" medium="image" fileSize="423055">
        <media:title type="plain">Illustration of abdominal aortic aneurysm</media:title>
      </media:content>
    </item>
    <item>
      <title>Meril’s Myval heart valve just as good as market leader devices</title>
      <description>
        <![CDATA[Data from Meril Life Sciences Pvt Ltd.’s Landmark trial showed that its series of Myval transcatheter heart valves were non-inferior compared with Edwards Lifesciences Corp.’s Sapien BEV and Medtronic plc’s Evolut SEV devices, with regards to safety and effectiveness in patients undergoing transcatheter aortic valve implantation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708273</guid>
      <pubDate>Thu, 16 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708273-merils-myval-heart-valve-just-as-good-as-market-leader-devices</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Merils-Myval-Octacor-valve-16may24.webp?t=1715896707" type="image/jpeg" medium="image" fileSize="108319">
        <media:title type="plain">Merils Myval Octacor valve</media:title>
        <media:description type="plain">Meril’s Myval valve. Credit: Meril Life Sciences</media:description>
      </media:content>
    </item>
    <item>
      <title>Safety of Elixir’s Lithix Hertz contact lithotripsy catheter validated</title>
      <description>
        <![CDATA[Elixir Medical Corp. revealed that data from the Pinnacle I study has validated the safety and effectiveness of its Lithix Hertz contact intravascular lithotripsy system to treat moderate to severe calcified coronary artery lesions by percutaneous transluminal coronary angioplasty.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708272</guid>
      <pubDate>Thu, 16 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708272-safety-of-elixirs-lithix-hertz-contact-lithotripsy-catheter-validated</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/intravascular-image-optical-coherence-tomography-showing-large-cracks-in-plaque.webp?t=1715896139" type="image/jpeg" medium="image" fileSize="200863">
        <media:title type="plain">intravascular-image-optical-coherence-tomography-showing-large-cracks-in-plaque.jpg</media:title>
        <media:description type="plain">Intravascular images (optical coherence tomography) showing large cracks in plaque. Credit: Elixir</media:description>
      </media:content>
    </item>
    <item>
      <title>Medtronic touts data for Resolute Onyx, Picardia data indicates TAVR shortcut</title>
      <description>
        <![CDATA[Following last week’s FDA approval of its Onyx Frontier drug eluting stent (DES), Medtronic plc released results at EuroPCR from a real-world, multicenter prospective study using its Resolute Onyx platform for percutaneous coronary interventions (PCI) in the left main artery. Rehovot, Israel-based Pi-Cardia Ltd. also released early data for patients treated with its Short Cut transcatheter device for coronary obstruction prevention.]]>
      </description>
      <guid>http://www.bioworld.com/articles/519036</guid>
      <pubDate>Fri, 20 May 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/519036-medtronic-touts-data-for-resolute-onyx-picardia-data-indicates-tavr-shortcut</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/Europcr-main-stage.webp?t=1653082112" type="image/png" medium="image" fileSize="926188">
        <media:title type="plain">Presentation on the EuroPCR 2022 main stage</media:title>
        <media:description type="plain">EuroPCR meeting in Paris
</media:description>
      </media:content>
    </item>
    <item>
      <title>1-year data for next-generation Navitor valve shows improved AS outcomes</title>
      <description>
        <![CDATA[Abbott Laboratories Inc. presented one-year outcomes from its PORTICO NG study assessing the latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor in patients with severe aortic stenosis. The valve, which includes a new active sealing cuff, builds on the company’s Portico transcatheter heart valve platform. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/518961</guid>
      <pubDate>Thu, 19 May 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/518961-1-year-data-for-next-generation-navitor-valve-shows-improved-as-outcomes</link>
    </item>
    <item>
      <title>Abbott report real-world outcomes for Triclip device </title>
      <description>
        <![CDATA[Abbott Laboratories Inc. reported 30-day results from its Triclip Bright Study at the EuroPCR meeting in Paris on May 19. The real-world outcomes showed that the company’s tricuspid repair systems Triclip and Triclip G4 transcatheter edge-to-edge repair (TEER) significantly reduced tricuspid regurgitation (TR) and substantially improved the quality of life across a wide range of anatomically diverse patients.]]>
      </description>
      <guid>http://www.bioworld.com/articles/518960</guid>
      <pubDate>Thu, 19 May 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/518960-abbott-report-real-world-outcomes-for-triclip-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/05-19-EuroPCR.webp?t=1652996292" type="image/png" medium="image" fileSize="706579">
        <media:title type="plain">EuroPCR meeting in Paris</media:title>
        <media:description type="plain">EuroPCR meeting in Paris</media:description>
      </media:content>
    </item>
    <item>
      <title>Jenavalve debut real-world results for Trilogy valve in severe AR patients</title>
      <description>
        <![CDATA[Jenavalve Technology Inc. presented first real-world data for a study evaluating the safety and efficacy of its Jenavalve Trilogy transcatheter aortic valve implantation (TAVI) system for the treatment of severe aortic regurgitation (AR). The data, presented at the EuroPCR meeting on May 18, met the primary safety and efficacy endpoints with no major adverse events and no moderate or severe AR at discharge.]]>
      </description>
      <guid>http://www.bioworld.com/articles/518915</guid>
      <pubDate>Wed, 18 May 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/518915-jenavalve-debut-real-world-results-for-trilogy-valve-in-severe-ar-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/05-18-EuroPCR-General.webp?t=1652909279" type="image/png" medium="image" fileSize="706579">
        <media:title type="plain">EuroPCR meeting</media:title>
        <media:description type="plain">EuroPCR meeting
</media:description>
      </media:content>
    </item>
    <item>
      <title>Robocath reports results from robotic coronary angioplasty study</title>
      <description>
        <![CDATA[Robocath SAS presented results from the R-Evolution European clinical study assessing the safety and efficacy of its R-One robot for coronary angioplasty procedures. The study, which included 62 patients across six European centers, met all three primary endpoints, showing 100% clinical success, >95% technical success, and 84.5% average reduction in physician radiation exposure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/518914</guid>
      <pubDate>Wed, 18 May 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/518914-robocath-reports-results-from-robotic-coronary-angioplasty-study</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/05-18-R-One.webp?t=1652912752" type="image/png" medium="image" fileSize="1136272">
        <media:title type="plain">R-One</media:title>
        <media:description type="plain">Robocath's R-One robot</media:description>
      </media:content>
    </item>
    <item>
      <title>Boston Scientific touts TAVR data for second generation Neo2 valve</title>
      <description>
        <![CDATA[The second generation of Boston Scientific Corp.’s Acurate Neo2 valve has demonstrated better performance than its predecessor, showing a threefold reduction of paravalvular leakage (PVL) said researchers. During the hotline/late-breaking trials session on May 17 at the EuroPCR meeting held in Paris, Andrea Buono, interventional cardiologist at Fondazione Poliambulanza Istituto Ospedaliero in Brescia, Italy, presented results from a large study comparing the performance of Acurate Neo and Acurate Neo2 in 13 Italian centers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/518892</guid>
      <pubDate>Tue, 17 May 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/518892-boston-scientific-touts-tavr-data-for-second-generation-neo2-valve</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/05-17-EuroPCR.webp?t=1652822640" type="image/png" medium="image" fileSize="905753">
        <media:title type="plain">Women taking notes during EurpPCR presentation</media:title>
        <media:description type="plain">The 2022 EuroPCR meeting is being held May 17-20 in Paris.</media:description>
      </media:content>
    </item>
    <item>
      <title>Medtronic offers new data backing RDN system for blood pressure control</title>
      <description>
        <![CDATA[Medtronic plc has presented three-year data on its global, multicenter, blinded, randomized and sham-controlled renal denervation (RDN) clinical program Spyral HTN-ON MED during the late-breaking clinical trial session at EuroPCR on May 17. The trial enrolled 80 typical uncontrolled hypertensive patients, randomized to RDN or sham control.]]>
      </description>
      <guid>http://www.bioworld.com/articles/518891</guid>
      <pubDate>Tue, 17 May 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/518891-medtronic-offers-new-data-backing-rdn-system-for-blood-pressure-control</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/3-30-Medtronic-Symplicity-Spyral.webp?t=1585605773" type="image/png" medium="image" fileSize="358899">
        <media:title type="plain">3-30-Medtronic-Symplicity-Spyral.png</media:title>
        <media:description type="plain">Symplicity Spyral renal denervation system. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Boston Scientific’s Neo2 outshines forerunner in new studies</title>
      <description>
        <![CDATA[Boston Scientific Corp. presented late-breaking data at EuroPCR 2021 demonstrating positive procedural performance for its Acurate Neo2 aortic valve system, including low rates of paravalvular leakage (PVL) and permanent pacemaker implementation (PPI). The findings are good news, following the older Acurate Neo&rsquo;s failure to demonstrate noninferiority to Medtronic plc&rsquo;s Evolut R in the so-called SCOPE II study.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507283</guid>
      <pubDate>Wed, 19 May 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507283-boston-scientifics-neo2-outshines-forerunner-in-new-studies</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/05-19-Boston-Scientific-Acurate-Neo2.webp?t=1621459216" type="image/png" medium="image" fileSize="319521">
        <media:title type="plain">Acurate Neo2 device image</media:title>
        <media:description type="plain">Acurate Neo2 aortic valve system. Credit: Boston Scientific Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Low-risk TAVR patients 'do exceptionally well' two years after Evolut implantation</title>
      <description>
        <![CDATA[Two-year results from the Evolut Low Risk Trial show Medtronic plc&rsquo;s Evolut transcatheter aortic valve replacement (TAVR) is noninferior to open-heart surgery in younger, healthier aortic stenosis patients. Moreover, the Evolut cohort fared better on certain critical events. Specifically, two-year rates of all-cause mortality or disabling stroke were 4.3% for TAVR patients vs. 6.3% for those undergoing surgical aortic valve repair (SAVR).]]>
      </description>
      <guid>http://www.bioworld.com/articles/507231</guid>
      <pubDate>Tue, 18 May 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507231-low-risk-tavr-patients-do-exceptionally-well-two-years-after-evolut-implantation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/05-18-Medtronic-Evolut-PRO.webp?t=1621370999" type="image/png" medium="image" fileSize="390920">
        <media:title type="plain">Evolut Pro+ device image</media:title>
        <media:description type="plain">Evolut Pro+ TAVR system. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Elixir Medical sees positive data for adaptive remodeling coronary stent technology</title>
      <description>
        <![CDATA[Elixir Medical Corp., reported positive 12-month results for its Dynamx Coronary Bioadaptor System, with no target vessel revascularization (TVR) or stent thrombosis and adaptive remodeling of the artery to sustain healthy blood flow. The findings, from a multisite European trial, were presented during a late-breaking trials session at the PCR e-Course virtual meeting in Paris.]]>
      </description>
      <guid>http://www.bioworld.com/articles/436085</guid>
      <pubDate>Mon, 29 Jun 2020 11:30:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436085-elixir-medical-sees-positive-data-for-adaptive-remodeling-coronary-stent-technology</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/6-26-Elixir-DynamX.webp?t=1593204401" type="image/png" medium="image" fileSize="948325">
        <media:title type="plain">Illustration of device in artery</media:title>
        <media:description type="plain">Dynamx Coronary Bioadaptor system. Credit: Elixir Medical Corp. </media:description>
      </media:content>
    </item>
    <item>
      <title>Abbott rolls out slew of data on minimally invasive structural heart implants</title>
      <description>
        <![CDATA[Minimally invasive structural heart implants are moving from mitral into tricuspid valve repair, as well as mitral valve replacement. Abbott Laboratories is presenting its latest data on all these fronts at the virtual PCR e-Course held by the European Association of Percutaneous Cardiovascular Interventions from June 25 to 27. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/436087</guid>
      <pubDate>Fri, 26 Jun 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436087-abbott-rolls-out-slew-of-data-on-minimally-invasive-structural-heart-implants</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/1-13-Abbott-Mitraclip.webp?t=1593206168" type="image/png" medium="image" fileSize="828514">
        <media:title type="plain">Product image</media:title>
        <media:description type="plain">Mitraclip device. Credit: Abbott Laboratories</media:description>
      </media:content>
    </item>
  </channel>
</rss>
